Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing
Experimental Dermatology · 2025-02 · 34 (2)
DOI: 10.1111/exd.70062 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Experimental Dermatology, online erschienen am 16.02.2025. Verfasst von Luca Mastorino und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologic Clinic, Departement of Clinical Medicine, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The possibility of modulating the treatment regimen regarding dose reduction (de‐escalation) or dose augmentation (escalation) in psoriasis biological treatment has been of increasing interest. De‐escalation strategies include reducing the single therapeutic dose, the mg/kg ratio or the number of injections, or dose‐spacing (D‐S), that is, extending the interval between administrations. Data regarding dose de‐escalation, in particular D‐S, on IL‐23, are lacking to date. The present pilot study is a cohort study with a retrospective analysis of the general characteristics and effectiveness outcomes of psoriatic patients undergoing therapeutic biologic D‐S of risankizumab and guselkumab. Ninety‐four patients, 32 (34.04%) treated with guselkumab and 62 (65.96%) treated with risankizumab, underwent dose modulation by D‐S of 50% of the approved range. The mean PASI decreased from 12.15 (5.43 SD) to 0.15 (0.46 SD) at D‐S time. Attainment of PASI100 was rapid: 88.3% at the D‐S date, remaining stable over the following year, reaching 100% of patients observed 12 months after D‐S. Similar is the trend for PASI 90 and PASI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatologic Clinic, Departement of Clinical Medicine, University of Turin, Turin, Italy.
ORCID-Profile: Luca Mastorino, Pietro Quaglino, Simone Ribero
Zitieren
APA
Mastorino, L., Dapavo, P., Ortoncelli, M., Bongiovanni, E., Liao, Y., Leo, F., Quaglino, P., & Ribero, S. (2025). Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing. Experimental Dermatology, 34(2). https://doi.org/10.1111/exd.70062
Vancouver
Mastorino L, Dapavo P, Ortoncelli M, Bongiovanni E, Liao Y, Leo F, et al. Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing. Experimental Dermatology. 2025;34(2). doi:10.1111/exd.70062
BibTeX
@article{Mastorino2025,
author = {Mastorino, Luca and Dapavo, Paolo and Ortoncelli, Michela and Bongiovanni, Eleonora and Liao, Yingying and Leo, Francesco and Quaglino, Pietro and Ribero, Simone},
title = {Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing},
journal = {Experimental Dermatology},
year = {2025},
volume = {34},
number = {2},
doi = {10.1111/exd.70062}
}
EUVIMED